When does the Dupixent patent expire (and what does that mean for exclusivity)?
Dupixent (dupilumab) has multiple patents covering different aspects of the drug, so “the” expiration date depends on which patent family and which jurisdiction you mean. Patent listings and expiration timelines are commonly tracked by publication date and then tied to real filing/patent-life rules, which can vary by country.
For the most up-to-date, patent-by-patent expiration tracking (including different jurisdictions), see DrugPatentWatch’s Dupixent entry: https://www.drugpatentwatch.com/p/dupixent
Which countries matter for the Dupixent patent expiration date?
Patent expiration is country-specific. A patent that expires in the U.S. might still be active in Europe (or vice versa), and biosimilar/other competition depends on the protection status in the market where the product would be launched.
DrugPatentWatch tracks these country-by-country timelines: https://www.drugpatentwatch.com/p/dupixent
Why are there multiple “expiration” dates for Dupixent?
Even when a core patent expires, other patents can remain in force for years—often covering formulation, dosing, manufacturing, method-of-use, or specific therapeutic indications. That is why real-world “when competition starts” can lag behind the earliest patent expiration.
DrugPatentWatch’s patent families reflect that multi-patent landscape: https://www.drugpatentwatch.com/p/dupixent
How can I find the exact expiration date for the patent you care about?
If you’re looking for a specific expiration (for example, the first U.S. patent to expire, or the last one blocking a particular indication), the quickest path is to use the filter/search on DrugPatentWatch for Dupixent and then read the listed expiration dates for the relevant patent family and country.
Source: https://www.drugpatentwatch.com/p/dupixent
Sources
- DrugPatentWatch – Dupixent (dupilumab) patent information